Eva Herweijer
Overview
Explore the profile of Eva Herweijer including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
21
Citations
252
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Dehlendorff C, Sparen P, Baldur-Felskov B, Herweijer E, Arnheim-Dahlstrom L, Ploner A, et al.
Vaccine
. 2018 Sep;
36(43):6373-6378.
PMID: 30249423
Background: Based on immunogenicity studies, a 2 dose HPV vaccination-schedule was recently recommended for girls younger than 15 years. We aimed to investigate the effectiveness of quadrivalent HPV (qHPV) vaccination...
12.
Herweijer E, Ploner A, Sparen P
Vaccine
. 2018 Mar;
36(15):1917-1920.
PMID: 29523448
Background: Between 2007 and 2011, opportunistic HPV-vaccination was available in Sweden and partially subsidized to girls aged 13-17, reaching a ∼30% overall coverage. Methods: All Swedish women/men aged 15-44 were...
13.
Sundstrom K, Herweijer E, Sparen P, Ploner A
Int J Cancer
. 2017 May;
141(2):416-418.
PMID: 28466483
No abstract available.
14.
Haggblom A, Lindback S, Gisslen M, Flamholc L, Hejdeman B, Palmborg A, et al.
PLoS One
. 2017 Feb;
12(2):e0171227.
PMID: 28207816
Background: As HIV infection needs a lifelong treatment, studying drug therapy duration and factors influencing treatment durability is crucial. The Swedish database InfCareHIV includes high quality data from more than...
15.
Bond E, Lu D, Herweijer E, Sundstrom K, Valdimarsdottir U, Fall K, et al.
BMC Infect Dis
. 2016 Aug;
16(1):419.
PMID: 27528204
Background: Loss of a loved one has consistently been associated with various health risks. Little is however known about its relation to sexually transmitted infections (STIs). Methods: We conducted a...
16.
Herweijer E, Sundstrom K, Ploner A, Uhnoo I, Sparen P, Arnheim-Dahlstrom L
Int J Cancer
. 2016 Feb;
138(12):2867-74.
PMID: 26856527
Human papillomavirus (HPV) types 16/18, included in HPV vaccines, contribute to the majority of cervical cancer, and a substantial proportion of cervical intraepithelial neoplasia (CIN) grades 2/3 or worse (CIN2+/CIN3+)...
17.
Herweijer E, Feldman A, Ploner A, Arnheim-Dahlstrom L, Uhnoo I, Netterlid E, et al.
PLoS One
. 2015 Jul;
10(7):e0134185.
PMID: 26218492
Background: Concerns have been raised that HPV-vaccination might affect women's cervical screening behavior. We therefore investigated the association between opportunistic HPV-vaccination and attendance after invitation to cervical screening. Methods: A...
18.
Ploner A, Herweijer E, Arnheim-Dahlstrom L
JAMA
. 2014 Jun;
311(23):2439-40.
PMID: 24938570
No abstract available.
19.
Herweijer E, Leval A, Ploner A, Eloranta S, Simard J, Dillner J, et al.
JAMA
. 2014 Feb;
311(6):597-603.
PMID: 24519299
Importance: Determining vaccine dose-level protection is essential to minimize program costs and increase mass vaccination program feasibility. Currently, a 3-dose vaccination schedule is recommended for both the quadrivalent and bivalent...
20.
Elfstrom K, Herweijer E, Sundstrom K, Arnheim-Dahlstrom L
Curr Opin Oncol
. 2013 Nov;
26(1):120-9.
PMID: 24248011
Purpose Of Review: As screening methods evolve and human papillomavirus (HPV) vaccination efforts gain traction, knowledge of the current evidence on effectiveness of prevention methods is critical to support further...